InVitae (NYSE:NVTA) issued its quarterly earnings data on Monday. The medical research company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.17), Briefing.com reports. InVitae had a negative return on equity of 134.68% and a negative net margin of 180.85%. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $24.18 million. During the same period in the previous year, the firm earned ($0.69) earnings per share. The company’s revenue was up 175.0% compared to the same quarter last year.
InVitae (NYSE:NVTA) opened at $6.09 on Wednesday. InVitae has a 52 week low of $3.80 and a 52 week high of $10.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61.
Several brokerages have weighed in on NVTA. JPMorgan Chase & Co. reduced their price objective on InVitae from $13.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday. Benchmark reduced their price objective on InVitae from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. Zacks Investment Research cut InVitae from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Leerink Swann cut their target price on InVitae from $14.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Finally, BidaskClub cut InVitae from a “hold” rating to a “sell” rating in a research note on Thursday, November 2nd. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $11.00.
TRADEMARK VIOLATION NOTICE: “InVitae (NVTA) Issues Quarterly Earnings Results” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/invitae-nvta-issues-quarterly-earnings-results.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.